Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(80.0%)

Phase 3

1(20.0%)

5Total

Phase 1(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07646210Phase 1Not Yet Recruiting

HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery

Role: lead

NCT07496372Phase 3Recruiting

A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)

Role: lead

NCT07471698Phase 1Not Yet Recruiting

hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease

Role: lead

NCT06340048Phase 1Active Not Recruiting

Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure

Role: lead

NCT06949137Phase 1Active Not Recruiting

Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Role: lead

All 5 trials loaded